Portal Hypertension Management Market Insights, Research and Growth Factor till 2033
North America currently holds the largest market share due to the high cost of technological advances in the healthcare system and a rise in beta-blocker consumption. Asia-Pacific has the second-largest market revenue due to an expanding older population and higher diagnosis rates. In the coming decade, North America is expected to dominate the market due to the increasing prevalence and occurrence of rare diseases and inpatient populations.
The global demand for transplantable organs is driving the growth of the Liver Transplantation segment. In the United States alone, around 122,913 diagnoses were awaiting organ transplants in 2019. As a result, there is a high demand for transplantation products to intervene in organ damage, leading to the expansion of the Liver Transplantation market.
Competitive Landscape
Key players in the Portal Hypertension Management market are Ono Pharmaceutical Co., Ltd., Chiasma, Inc., Genextra S.p.a., Gilead Sciences, Inc., Debiovision, Inc., Govind Ballabh Pant Hospital, Dr. Falk Pharma GmbH, Novartis AG, Sun Pharmaceuticals Industries Ltd.
Get More Details@ https://www.futuremarketinsights.com/reports/portal-hypertension-management-market
Key Segments Profiled in the Portal Hypertension Management Industry Survey
By Treatment:
- Liver Transplantation
- Endoscopic Therapy
- Banding
- Balloon Tamponade
- Shunting Procedures
- Nonsurgical Transjugular Intrahepatic Portal Systemic Shunt
- Surgical Shun
- Drug Class
- Octapeptides
- Cofactors
- PDE5 Inhibitor
- Beta Blockers
By End Users:
- Hospitals
- Specialty Clinic
- Others

Comments
Post a Comment